XML 90 R61.htm IDEA: XBRL DOCUMENT v3.24.1
Revenues from Contracts with Customers - Additional Information (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues € 3,819.0 € 17,310.6 € 18,976.7
Contract liabilities 751.8 125.5  
Remaining upfront fees contract liabilities   65.7  
Advance payment received for future COVID 19 vaccine sale   56.3  
Commercial revenues      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues 3,815.5 17,194.6 18,874.0
United States      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues 3,010.9 12,709.7 14,636.5
Germany      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues 482.7 3,031.0 2,241.9
Belgium      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues     675.0
Pfizer Inc.      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues 3,293.0 13,795.8 15,500.0
German Federal Ministry of Health      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues 473.6 3,020.5 1,945.6
Contract liabilities 302.3    
Sales to collaboration partners | Commercial revenues      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues 275.3 1,224.3 970.9
Sales to collaboration partners | Commercial revenues | Manufacturing Variances      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues 74.5 850.0 31.0
Direct product sales to customers | Commercial revenues      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues 473.6 € 3,184.7 3,007.2
Share of collaboration partners' sales milestones | Commercial revenues      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Total revenues     € 476.6
Pfizer (COVID-19 vaccine)      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Contract liabilities 386.4    
Pfizer (Zoster)      
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Remaining upfront fees contract liabilities € 62.3